Equities Analysts Issue Forecasts for STOK FY2025 Earnings

Key Points

• Cantor Fitzgerald has upgraded its earnings estimates for Stoke Therapeutics, projecting FY2025 EPS of $0.27, a significant increase from their previous estimate of ($0.34), and maintains a "Strong-Buy" rating on the stock.
• Stoke Therapeutics reported quarterly earnings of ($0.40), which exceeded analysts' expectations of ($0.57), though revenue fell short of estimates at $13.82 million compared to a consensus of $31.51 million.
• Several analysts have issued ratings on Stoke Therapeutics, with an average rating of "Buy" and a consensus price target of $25.17, reflecting a generally positive outlook from market experts.

Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a note issued to investors on Wednesday, August 13th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will post earnings per share of $0.27 for the year, up from their previous forecast of ($0.34). Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Stoke Therapeutics' current full-year earnings is ($2.01) per share. Cantor Fitzgerald also issued estimates for Stoke Therapeutics' FY2026 earnings at ($2.69) EPS.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.17. Stoke Therapeutics had a return on equity of 18.32% and a net margin of 26.25%. The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $31.51 million.

Other equities research analysts have also recently issued research reports about the company. HC Wainwright dropped their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Chardan Capital reiterated a "buy" rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, August 13th. Jefferies Financial Group assumed coverage on Stoke Therapeutics in a report on Friday, July 18th. They issued a "buy" rating and a $30.00 price objective for the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday, July 1st. Finally, Wedbush lifted their price target on Stoke Therapeutics from $16.00 to $22.00 and gave the company an "outperform" rating in a research report on Wednesday, August 13th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Stoke Therapeutics presently has an average rating of "Buy" and an average target price of $25.57.

Stoke Therapeutics Stock Performance

STOK traded up $0.30 on Friday, hitting $18.51. 1,176,398 shares of the company were exchanged, compared to its average volume of 934,087. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $18.60. The firm has a fifty day simple moving average of $12.70 and a two-hundred day simple moving average of $10.20. The stock has a market capitalization of $1.01 billion, a PE ratio of 21.78 and a beta of 1.15.

Institutional Trading of Stoke Therapeutics

Several large investors have recently modified their holdings of the company. Wellington Management Group LLP grew its holdings in shares of Stoke Therapeutics by 0.9% in the first quarter. Wellington Management Group LLP now owns 135,960 shares of the company's stock worth $904,000 after acquiring an additional 1,148 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company's stock worth $162,000 after acquiring an additional 1,149 shares during the period. Graham Capital Management L.P. grew its holdings in Stoke Therapeutics by 8.5% during the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company's stock valued at $206,000 after purchasing an additional 1,453 shares during the period. BNP Paribas Financial Markets grew its holdings in Stoke Therapeutics by 66.2% during the second quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock valued at $48,000 after purchasing an additional 1,668 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC grew its holdings in Stoke Therapeutics by 2.0% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company's stock valued at $1,021,000 after purchasing an additional 1,791 shares during the period.

Insider Buying and Selling at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 13,712 shares of the business's stock in a transaction on Wednesday, August 13th. The stock was sold at an average price of $15.00, for a total value of $205,680.00. Following the completion of the transaction, the general counsel owned 19,631 shares in the company, valued at $294,465. The trade was a 41.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Barry Ticho sold 6,471 shares of the business's stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $10.03, for a total value of $64,904.13. Following the completion of the transaction, the insider owned 25,782 shares of the company's stock, valued at $258,593.46. This represents a 20.06% decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,432 shares of company stock valued at $345,775 in the last 90 days. Company insiders own 9.50% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.